RDY
Dr. Reddy's Posts Robust Q2 Performance Amid Global Headwinds
Dr. Reddy's, the Indian multinational pharmaceutical company, has reported a robust second quarter performance despite facing significant global headwinds. The company's revenue for the quarter ended September 30, 2026, stood at INR 8,671 crore ($905 million), a decline of 1.5% on year-over-year and a